MindRank AI: MindRank Begins IND-enabling Studies of its first AI-designed Drug, 8 Months After Program Initiation

HANGZHOU, China, Jan. 18, 2022 /PRNewswire/ -- MindRank AI, an artificial intelligence (AI) driven biotech company, today announced that the company has nominated a preclinical candidate (PCC)

Related Keywords

China ,Hangzhou ,Zhejiang ,Zhangming Niu ,Months After Program Initiation ,After Program ,Mindrank ,Egins ,Nabling ,Studies ,First ,Esigned ,Drug ,Months ,After ,Program ,Initiation ,